Beyond Data Transparency: Innovation Across the Drug Development Lifecycle

Beyond Data Transparency: Innovation Across the Drug Development Lifecycle

This session was originally broadcast as part of the CBI Publication and Clinical Trial Transparency Conference on September 23, 2020

 

About this webinar

Beyond Data Transparency: Innovation Across the Drug Development Lifecycle

Once a drug company has clinical trial transparency (CTT) capabilities in place, new opportunities to drive value further along the drug development life cycle also emerge.

In this presentation, General Manager Sarah Lyons discusses how risk-based, statistical anonymization protects patient privacy while enabling insight-rich data, helping you:

  • Achieve trial transparency
  • Meet regulatory deadlines
  • Drive drug differentiation
  • Accelerate data science

If you’re looking to comply with drug authorization regulations, share insight-rich data with health researchers, or scale anonymization for internal data strategies and drug development, this presentation is for you.

Presenter

Sarah Lyons, General Manager

Sarah helps Privacy Analytics’ clients earn trust and execute on their use priorities. Her career has often involved developing and implementing innovative risk assessment methodologies for governments and Fortune 500 companies. She has worked with decision makers at the highest level to identify and address financial, political and/or reputational risk before any harm could be done to the organization. Her previous roles include Partner and National Privacy Services Leader at MNP LLP, COO of A Hundred Answers Inc., and IT Risk Advisory Practice Lead for Ernst & Young Ottawa.

Sarah Lyons

General Manager

Join the next 5 Safes Data Privacy webinar

This course runs on the 2nd Wednesday of every month, at 11 a.m. ET (45 mins). Click the button to register and select the date that works best for you.